Advyzon Investment Management LLC Buys 4,774 Shares of Pfizer Inc. $PFE

Advyzon Investment Management LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 34.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,715 shares of the biopharmaceutical company’s stock after acquiring an additional 4,774 shares during the period. Advyzon Investment Management LLC’s holdings in Pfizer were worth $454,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Westbourne Investments Inc. acquired a new stake in Pfizer in the 1st quarter worth approximately $2,411,000. Bourne Lent Asset Management Inc. grew its stake in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares during the period. Strs Ohio purchased a new position in shares of Pfizer in the first quarter worth about $49,968,000. IFM Investors Pty Ltd grew its holdings in Pfizer by 3.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after buying an additional 41,263 shares in the last quarter. Finally, Intrua Financial LLC boosted its holdings in Pfizer by 17.4% in the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after purchasing an additional 11,643 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $25.49 on Wednesday. The firm has a market cap of $144.93 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $24.75 and its two-hundred day moving average is $24.41. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.